Understanding how different forms of TDP43 contribute to ALS and frontotemporal dementia
Official title: Identifying the function of alternatively spliced TDP43 isoforms and contribution to disease
Funded at University of Michigan at Ann Arbor · NIH-10993093 · Data updated 2026-11-12
This study is looking at how different forms of a protein called TDP43 might contribute to the nerve damage seen in ALS and frontotemporal dementia, with the hope of finding new ways to treat these conditions.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | August 1, 2023 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $42,600 |
| NIH project number | 5F31NS134123-02 |
| Project ID | NIH-10993093 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with ALS or FTD, particularly those with familial forms of these diseases.
✕Less likely to help
Patients with other neurodegenerative disorders unrelated to TDP43 mislocalization may not benefit from this research.
What this research studies
This research investigates the role of alternatively spliced TDP43 isoforms in the development of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). By examining how these isoforms mislocalize and accumulate in neurons, the study aims to uncover the mechanisms that lead to neurodegeneration. The approach includes defining the interactions of these isoforms with other proteins and exploring their impact on RNA stability. This research could provide insights into new therapeutic targets for these debilitating conditions.
Why it matters
Potential benefit: If successful, this research could lead to the development of new treatments that modify the progression of ALS and FTD.
How similar studies have gone: Previous research has shown promising results in understanding TDP43's role in neurodegeneration, suggesting that this approach could yield valuable insights.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Dykstra, Megan — University of Michigan at Ann Arbor
- Study coordinator: Dykstra, Megan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.